论文部分内容阅读
根据日本评论家提供的情况,该国制药公司正在开发的11种新药可能成为“重磅炸弹”。 三共公司和卫材公司将是重要的受益者,它们各有两个产品上榜(该榜由医药论坛协会会长中村健次先生辑成)。三共公司的糖尿病口服治疗药Noscal(troglitazone)及注射
According to Japanese commentators, the 11 new drugs being developed by the country’s pharmaceutical companies may become “blockbusters.” San Gong Gong and Wei Xiang Company will be important beneficiaries. They each have two products on the list (this list is compiled by Mr. Nakamura, President of the Medical Forum Association). Sansei Corporation’s Diabetic Oral Drug Noscal (troglitazone) and Injection